@article{179996,
  author = {Aartjan Te Velthuis and Tatiana Zubkova and Megan Shaw and Andrew Mehle and David Boltz and Norbert Gmeinwieser and Holger Stammer and Jens Milde and Lutz M{\"u}ller and Victor Margitich},
  title = {Enisamium reduces influenza virus shedding and improves patient recovery by inhibiting viral RNA polymerase activity},
  abstract = { Infections with respiratory viruses constitute a huge burden on our health and economy. Antivirals against some respiratory viruses are available, but further options are urgently needed. Enisamium iodide (laboratory code FAV00A, trade name Amizon{\textregistered}) is an antiviral marketed in countries of the Commonwealth of Independent States for the treatment of viral respiratory infections, but its clinical efficacy and mode of action are not well understood. Here, we investigated the efficacy of enisamium in patients aged between 18-60 years with confirmed influenza and other viral respiratory infections. Enisamium treatment resulted in reduced influenza virus shedding (at day 3, 71.2\% in enisamium group tested negative versus 25.0\% in placebo group, p },
  year = {2021},
  journal = {Antimicrob Agents Chemother},
  month = {02/2021},
  issn = {1098-6596},
  doi = {10.1128/AAC.02605-20},
  language = {eng},
}